Ligand Pharmaceuticals (LGND) investor relations material

Executive summary

• Achieved strong Q2 2026 results with total revenue up 34% year-over-year to $64 million and royalty revenue up 32% to $48 million, driven by Filspari, Ohtuvayre, and ZELSUVMI.

• Completed the largest transaction in company history: acquisition of XOMA Royalty, adding over 120 assets and more than doubling the royalty portfolio to over 200 assets, including seven commercial products and 14 late-stage programs.

• Executed a $700 million zero coupon convertible note offering, enhancing capital flexibility and providing $679 million in net proceeds, with $60 million used for share repurchases.

• Adjusted diluted EPS grew 48% year-over-year to $2.37, with updated 2026 guidance of $9–$9.50 per share.

• Net income for Q2 2026 was $48.5 million, up from $4.8 million in Q2 2025, reflecting higher royalty income and investment gains.

Financial highlights

• Q2 2026 total revenue reached $64 million, up 34% year-over-year, with royalty revenue at $48 million, up 32% year-over-year.

• Adjusted EPS rose 48% to $2.37; GAAP net income was $48.5 million, and adjusted net income was $50.8 million.

• Cash and investments totaled $1.36 billion at June 30, 2026, with $700 million in deployable capital post-XOMA acquisition.

• Operating cash flow expected to exceed $200 million in 2026 and reach $300 million in 2027.

• Travere's Filspari U.S. net sales grew 96% year-over-year to $141 million; Merck's Ohtuvayre net sales grew 98% to $204 million.

Outlook and guidance

• 2026 royalty revenue guidance: $225–$250 million; total revenue: $270–$310 million; Captisol: $35–$40 million; contract revenue: $10–$20 million.

• Adjusted EPS guidance raised to $9.00–$9.50, reflecting cost synergies and share repurchase.

• XOMA acquisition expected to contribute $0.50 adjusted EPS in H2 2026 and $1.50 in 2027.

• Majority of remaining Captisol and contract revenue expected in Q4 2026.

• Updated five-year outlook to be provided at Investor Day in December.